<SEC-DOCUMENT>0001628280-21-015854.txt : 20210805
<SEC-HEADER>0001628280-21-015854.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805161133
ACCESSION NUMBER:		0001628280-21-015854
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		211148284

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>auph-20210805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3c706e47-e7c4-45a6-976f-e0c2c621eb5e,g:cf0e529d-5d42-4d30-9e7d-fc368e360cf2,d:913372efdb7945d6a6b4b49bd570b0d2--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>auph-20210805</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl80L2ZyYWc6NGRkZjU3MmEzZmUyNGQzYzg0ZGYxZjc4MjZjMDY5Y2UvdGFibGU6MjhmMWIwZjJjNTA4NDk2Mjk0ZTMwZjczMGJlYTgwMTIvdGFibGVyYW5nZToyOGYxYjBmMmM1MDg0OTYyOTRlMzBmNzMwYmVhODAxMl8xLTEtMS0xLTA_a8f5ff21-603a-404f-9255-726e21bf1b03">0001600620</ix:nonNumeric><ix:nonNumeric contextRef="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl80L2ZyYWc6NGRkZjU3MmEzZmUyNGQzYzg0ZGYxZjc4MjZjMDY5Y2UvdGFibGU6MjhmMWIwZjJjNTA4NDk2Mjk0ZTMwZjczMGJlYTgwMTIvdGFibGVyYW5nZToyOGYxYjBmMmM1MDg0OTYyOTRlMzBmNzMwYmVhODAxMl8yLTEtMS0xLTA_06cfe927-5741-4408-976c-10a4082f505c">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="auph-20210805.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-07</xbrli:startDate><xbrli:endDate>2021-06-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i913372efdb7945d6a6b4b49bd570b0d2_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM3_d8cded71-7d91-4acf-b2b1-a85a7a22bc12">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18yMjU_95a8e758-32db-4580-8cbc-97cb3d82d075">August 5, 2021</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM0_0f8f0007-7c45-4576-9750-9fbeeaddc168">Aurinia Pharmaceuticals Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NzU0ZTYwZWIxMjg0NDE1OThmNjEzYWZmZDc5MzA2OTYvdGFibGVyYW5nZTo3NTRlNjBlYjEyODQ0MTU5OGY2MTNhZmZkNzkzMDY5Nl8wLTAtMS0xLTA_afd40e8b-901a-4700-bcfa-182aa2a02b98">Canada</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NzU0ZTYwZWIxMjg0NDE1OThmNjEzYWZmZDc5MzA2OTYvdGFibGVyYW5nZTo3NTRlNjBlYjEyODQ0MTU5OGY2MTNhZmZkNzkzMDY5Nl8wLTItMS0xLTA_bd7cadb9-70e9-42a2-bef6-7e701ce15c58">001-36421</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NzU0ZTYwZWIxMjg0NDE1OThmNjEzYWZmZDc5MzA2OTYvdGFibGVyYW5nZTo3NTRlNjBlYjEyODQ0MTU5OGY2MTNhZmZkNzkzMDY5Nl8wLTQtMS0xLTA_e65df63e-3949-4fb7-bb16-2f702eb403ef">46-4129078</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Commission File No.)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM1_b6543188-58e7-4e9d-b0eb-ca3ad3cd492a">#1203-4464 Markham Street</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMz_8cabe31d-76a1-48bd-847e-21a39bca0b1e">Victoria</ix:nonNumeric>, <ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM2_27c75ef5-9be3-4c15-a856-9a2df835722d">British Columbia</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjI5_ec22b039-d213-4293-a161-3169d65649bc">V8Z 7X8</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">(<ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMw_f784016b-9c9e-4578-bd1c-04ac3bfdb675">250</ix:nonNumeric>) <ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMx_b6ca18cf-0f36-4e08-b7e0-4fb8bc5b8871">708-4272</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">(Address and telephone number of registrant's principal executive offices)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6MGQwOGE5NGEwNmUwNDdkNWE5ZTc1OTc1OWQ2NjM3N2UvdGFibGVyYW5nZTowZDA4YTk0YTA2ZTA0N2Q1YTllNzU5NzU5ZDY2Mzc3ZV8wLTAtMS0xLTA_6af21139-d741-4d5c-957c-b1c87e53681f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NjE2ZDAxMWE4MjllNDgzYzg4YWJmNjhiMTM2YjZhZDYvdGFibGVyYW5nZTo2MTZkMDExYTgyOWU0ODNjODhhYmY2OGIxMzZiNmFkNl8wLTAtMS0xLTA_caf37297-e97b-4f61-b421-6eaf089ba265">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6MThiYTVlMzIzNzI2NDdhMjhmNjg2NGMyMWI0YWJjOTUvdGFibGVyYW5nZToxOGJhNWUzMjM3MjY0N2EyOGY2ODY0YzIxYjRhYmM5NV8wLTAtMS0xLTA_80e45758-4777-4241-ab7e-5a9ac2c51d07">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6OWYxNjE4YmJjZjZlNGNhMmFkMmI5NjdlM2UwYmQxZmQvdGFibGVyYW5nZTo5ZjE2MThiYmNmNmU0Y2EyYWQyYjk2N2UzZTBiZDFmZF8wLTAtMS0xLTA_2b2ae757-b892-453a-ac49-9df360dbc8d4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of Each Exchange on which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NTQ2YTdlNmM4ODIxNDA1MTkzNmIzZmQxZjFlOTViOGQvdGFibGVyYW5nZTo1NDZhN2U2Yzg4MjE0MDUxOTM2YjNmZDFmMWU5NWI4ZF8xLTAtMS0xLTA_e1b5ee2c-db37-428e-a9a9-1a9a77d57ea4">Common Shares, without par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NTQ2YTdlNmM4ODIxNDA1MTkzNmIzZmQxZjFlOTViOGQvdGFibGVyYW5nZTo1NDZhN2U2Yzg4MjE0MDUxOTM2YjNmZDFmMWU5NWI4ZF8xLTItMS0xLTA_f350af01-9bf1-48c4-8d4e-540c35f96eeb">AUPH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NTQ2YTdlNmM4ODIxNDA1MTkzNmIzZmQxZjFlOTViOGQvdGFibGVyYW5nZTo1NDZhN2U2Yzg4MjE0MDUxOTM2YjNmZDFmMWU5NWI4ZF8xLTQtMS0xLTA_b5421e3b-b36b-40b6-aa75-7b907d145533">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMy_058f5382-bc8f-43ed-9353-0a0111776b83">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#160;&#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i913372efdb7945d6a6b4b49bd570b0d2_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, Aurinia Pharmaceuticals Inc. ("Aurinia") issued a press release announcing its financial results for the quarter ended June&#160;30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto, that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(d) Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_q22021pressrele.htm">Press release dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_q22021pressrele.htm"> August 5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_q22021pressrele.htm">, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:1pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i913372efdb7945d6a6b4b49bd570b0d2_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">SIGNATURES</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: August&#160;5, 2021</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.055%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AURINIA PHARMACEUTICALS INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_q22021pressrele.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5328910faba54a98ac30e807ce4cb42b_1"></div><div style="min-height:115.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr><tr style="height:75pt"><td colspan="9" style="padding:0 1pt"><div><img alt="aurinalogoa.jpg" src="aurinalogoa.jpg" style="height:103px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS</font></div><div><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021) &#8211; </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.33pt">415 patient start forms (PSFs) received for LUPKYNIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Continued ex-U.S. execution highlighted by the submission of a voclosporin MAA to the EMA by Otsuka -</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Cash and cash equivalents, and investments of $323.7 million at June&#160;30, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8211; </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Conference call to be hosted today at 4&#58;30 p.m. EDT -</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VICTORIA, British Columbia &#8211; August 5, 2021 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Aurinia Pharmaceuticals Inc. (NASDAQ&#58; AUPH) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;) today issued its financial results for the second quarter ended June&#160;30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Aurinia continues to make progress toward transforming the treatment of lupus nephritis (LN) by improving access to treatment and providing disease education and care for the long underserved LN patient community,&#8221; said Peter Greenleaf, President and Chief Executive Officer of Aurinia. &#8220;Our second quarter results demonstrate our momentum as COVID-related restrictions are loosened in parts of the United States with a significant increase in both revenue and patient start forms. We are confident that with this year-to-date performance and a strong balance sheet, that we are well-poised for growth as we continue our work to expand the treatment of LN and seek new opportunities that could address the needs of patients with serious autoimmune disorders.&#8221;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Greenleaf further stated, &#8220;As we continue to expand patient access to LUPKYNIS across the United States, we anticipate that annual net revenue for LUPKYNIS will be in the range of $40 to $50 million for 2021, setting Aurinia up for a very strong 2022 as we recognize the benefit of patients continuing on therapy and hopefully achieving reductions in their proteinuria.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Quarter 2021 U.S. Commercial Activities</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">415 PSFs during the second quarter with over 800 PSFs received year-to-date&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">As of June 30, 2021, a total of 45 LUPKYNIS-specific policies had been published by insurers representing approximately 110 million covered lives in the U.S.&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Converted over 50% of PSFs to patients on therapy by the end of the second quarter. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Operational Developments </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">On May 10, 2021, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an international, peer-reviewed medical journal, published the results of the Company&#8217;s Phase 3 AURORA-1 study evaluating LUPKYNIS (voclosporin) in adults with LN. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">On May 20, 2021, the Company announced that the interim analysis of the AURORA-2 continuation study showed that subjects in the LUPKYNIS treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate (eGFR) at 104 weeks of treatment.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Effective June 14, 2021, the Company appointed Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company&#8217;s Board of Directors. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">On June 25, 2021, Aurinia&#8217;s licensing partner, Otsuka Pharmaceutical Co., Ltd., filed an initial marketing authorization application (MAA) with the European Medicines Agency (EMA) seeking approval for the use of voclosporin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of adult patients with active LN in the European Union, as well as Norway, Iceland and Liechtenstein. Upon approval the Company would be eligible for up to an additional $30 million in approval related milestones, low double-digit royalties on sales, and additional revenues for the supply of product to Otsuka under a cost-plus arrangement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Upcoming Milestones</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Aurinia anticipates reporting top-line results from the ongoing AURORA-2 two-year continuation study of voclosporin for the treatment of LN by the end of 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Liquidity at June&#160;30, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, Aurinia had cash and cash equivalents and investments of $323.7 million compared to $422.7 million at December&#160;31, 2020. The decrease was primarily related to the commercial infrastructure spend to support the launch of LUPKYNIS, payments for inventory and an upfront payment made as part of a collaborative agreement with Lonza to build a dedicated manufacturing capability (or monoplant).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $91.5 million for the six months ended June&#160;30, 2021 compared to $44.6 million for the six months ended June&#160;30, 2020. The increase was primarily due to the commercial infrastructure spend to support the launch of LUPKYNIS, payments for inventory and a one-time payment to a related party upon achievement of specific milestones. In the prior year, the Company was still in the development phase of LUPKYNIS and as a result, did not incur any material related selling expenses.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has sufficient financial resources to fund its current plans, which include funding commercial activities, including FDA related post approval commitments, manufacturing and packaging of commercial drug supply, conducting planned research and development (R&#38;D) programs, and operating activities into at least 2023.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results for the Quarter Ended June&#160;30, 2021</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarter ended June&#160;30, 2021, Aurinia recorded a net loss of $47.0 million or $0.37 net loss per common share, as compared to a net loss of $26.5 million or $0.24 net loss per common share for the quarter ended June&#160;30, 2020. For the six months ended June&#160;30, 2021, Aurinia recorded a net loss of $97.4 million or $0.76 net loss per common share as compared to a net loss of $52.5 million or $0.47 net loss per common share.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $6.6 million and $29 thousand for the quarters ended June&#160;30, 2021 and June&#160;30, 2020, respectively. Total revenue was $7.5&#160;million and $59&#160;thousand for the six months ended June&#160;30, 2021 and June&#160;30, 2020, respectively. The increase for both periods was primarily the result of the commercial sales of LUPKYNIS following FDA approval in January 2021.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales were $308 thousand and nil for the quarters ended June&#160;30, 2021 and June&#160;30, 2020, respectively. Cost of sales were $356&#160;thousand and nil for the six months ended June&#160;30, 2021 and June&#160;30, 2020, respectively. The increase for both periods was primarily the result of commercial sales of LUPKYNIS. Gross margin for the three and six months ended June&#160;30, 2021 was approximately 95%.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&#38;A) expenses were $43.8 million and $15.4 million for the quarters ended June&#160;30, 2021 and June&#160;30, 2020, respectively. For the six months ended June&#160;30, 2021 and June&#160;30, 2020, SG&#38;A expenses were $83.1 million and $26.5 million, respectively. The increase for both periods was primarily due to the expansion of the commercial infrastructure, administrative functions and patient assistance programs to support the launch of LUPKYNIS. SG&#38;A share-based compensation expense for the three and six months ended June&#160;30, 2021 was $6.5 million and $13.2 million, respectively.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&#38;D expenses were $10.1 million and $11.1 million for the quarters ended June&#160;30, 2021 and June&#160;30, 2020, respectively. For the six months ended June&#160;30, 2021 and June&#160;30, 2020, R&#38;D expenses were $19.9 million and $24.9 million, respectively. The decrease for both periods was primarily due to lower contract research organization expenses and other third-party clinical trial expenses following the approval of LUPKYNIS, including a reduction in new drug application preparation costs, capitalization of supply costs following approval, and termination of the dry eye trial during the fourth quarter of 2020. R&#38;D share-based compensation expense for the three and six months ended June&#160;30, 2021 was $1.1 million and $2.2 million, respectively.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release is intended to be read in conjunction with the Company&#8217;s unaudited condensed consolidated financial statements and Management's Discussion and Analysis for the quarter ended June&#160;30, 2021 in the Company&#8217;s Quarterly Report on Form 10-Q, which is accessible on Aurinia's website at www.auriniapharma.com, on SEDAR at www.sedar.com or on EDGAR at www.sec.gov&#47;edgar.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call Details</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia will host a conference call and webcast to discuss the quarter ended June&#160;30, 2021 financial results today, Thursday, August 5, 2021 at 4&#58;30 p.m. EDT. The audio webcast can be accessed under &#34;News&#47;Events&#8221; through the &#8220;Investors&#8221; section of the Aurinia corporate website at www.auriniapharma.com. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. &#38; Canada). An audio webcast can be accessed under &#34;News&#47;Events&#8221; through the &#8220;Investors&#8221; section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia&#8217;s website.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Lupus Nephritis</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LN is a serious progression of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S. and approximately one out of three of these individuals have already developed LN at the time of SLE diagnosis. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in kidney failure. Black and Asian individuals with SLE are four times more likely to develop LN and individuals with Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to Caucasian individuals.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Aurinia</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active LN. The Company&#8217;s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements or information with respect to&#58; Aurinia&#8217;s estimates as to annual net revenue in the range of $40-$50 million in 2021&#59; Aurinia&#8217;s estimates as to the number of patients with SLE in the U.S. and the proportion of those persons who will develop LN&#59; Aurinia being confident that it is well-poised for growth&#59; Aurinia&#8217;s belief that it has sufficient financial resources to fund its current plans until 2023&#59; and the planned timing for reporting top-line results from the ongoing AURORA-2 continuation study. It is possible that such results or conclusions may change. Words such as &#8220;anticipate&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;target&#8221;, &#8220;plan&#8221;, &#8220;goals&#8221;, &#8220;objectives&#8221;, &#8220;may&#8221; and other similar words and expressions, identify forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about&#58; the accuracy of reported data from third party studies and reports&#59; the number, and timing of receipt, of PSFs and their rate of conversion into patients on therapy&#59; that Aurinia&#8217;s intellectual property rights are valid and do not infringe the intellectual </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights of third parties&#59; Aurinia&#8217;s assumptions relating to the capital required to fund operations into 2023&#59; the assumption that Aurinia&#8217;s current good relationships with its suppliers, service providers and other third parties will be maintained&#59; assumptions relating to the burn rate of Aurinia&#8217;s cash for operations&#59; the relationship between COVID vaccinations and patient treatment&#59; and that Aurinia&#8217;s third party service providers will comply with their contractual obligations. Even though the management of Aurinia believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Aurinia to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following&#58; Aurinia&#8217;s actual future financial and operational results may differ from its expectations&#59; difficulties Aurinia may experience in completing the commercialization of voclosporin&#59; the market for the LN business may not be as estimated&#59; Aurinia may have to pay unanticipated expenses&#59; Aurinia may not be able to obtain sufficient supply to meet commercial demand for voclosporin in a timely fashion&#59; unknown impact and difficulties imposed by the COVID-19 pandemic on Aurinia&#8217;s business operations including nonclinical, clinical, regulatory and commercial activities&#59; the results from Aurinia&#8217;s clinical studies and from third party studies and reports may not be accurate&#59; Aurinia&#8217;s third party service providers may not, or may not be able to, comply with their obligations under their agreements with Aurinia&#59; and Aurinia&#8217;s assets or business activities may be subject to disputes that may result in litigation or other legal claims. Although Aurinia has attempted to identify factors that would cause actual actions, events, or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements, or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond Aurinia&#8217;s control. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking information contained in this press release is qualified by this cautionary statement. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia&#8217;s most recent Annual Report on Form 10-K available by accessing the Canadian Securities Administrators&#8217; System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission&#8217;s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov&#47;edgar, or on Aurinia&#8217;s website at www.auriniapharma.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Glenn Schulman, PharmD, MPH </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate Communications, Aurinia </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">gschulman&#64;auriniapharma.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Media&#47;Corporate Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dana Lynch </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate Communications, Aurinia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">dlynch&#64;auriniapharma.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i5328910faba54a98ac30e807ce4cb42b_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121,561</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,350&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">197,176</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,418</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,376</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">349,689</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,427&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,004</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,380&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,856</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,813</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and other intangible assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,291</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,332&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,615</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386,268</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,661&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,831</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,797&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,372</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,315</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,997&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,872</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,824</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,011</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,911&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHAREHOLDER&#8217;S EQUITY</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares - no par value, unlimited shares authorized, 128,396 and 126,725 shares issued and outstanding as at June 30, 2021 and December 31, 2020, respectively</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">954,572</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,328&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,383&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(792)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(672,545)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575,156)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholder&#8217;s equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332,257</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,750&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">386,268</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,661&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i5328910faba54a98ac30e807ce4cb42b_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,591</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,475</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,620</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,534</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,786</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,449&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83,068</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,091</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,076&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,924</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,059</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(967)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">804</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost and operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,754</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,892&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,982&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47,134)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,863)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97,677)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,923)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">314</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46,992)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,542)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97,363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,712)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47,010)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,544)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97,389)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,476)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.76)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding used in computation of basic and diluted loss per share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,222</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,576&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127,814</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,392&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>auph-20210805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c706e47-e7c4-45a6-976f-e0c2c621eb5e,g:cf0e529d-5d42-4d30-9e7d-fc368e360cf2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:auph="http://www.auriniapharma.com/20210805" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.auriniapharma.com/20210805">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20210805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20210805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.auriniapharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>auph-20210805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c706e47-e7c4-45a6-976f-e0c2c621eb5e,g:cf0e529d-5d42-4d30-9e7d-fc368e360cf2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_4a5be694-1644-48c4-88c6-0ccf40167585_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c8a18715-815c-48af-b201-fdfd3863f767_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_afcacff7-34fd-46cf-a711-93222317087d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f89d2776-7370-4049-af91-0f80027b4e93_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5b305794-ab2d-4359-8c41-d076b4fa9f39_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5c71e185-0fb4-4749-a194-cad295769849_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7d927673-cb69-4e09-bf11-979319fb936e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_216eb08b-c567-4d67-b60d-dc48808d9609_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3702bc64-ca52-456d-be3e-75e968fcbe06_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_e69b019e-18a0-45ab-90e4-7d818f6ae984_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_da64e9a5-8a77-40f1-a0f5-6fb7f63dcf1b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_40415bd1-1699-4143-92a8-c02af04ddcd6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9552341f-d320-4318-aaa7-49c3a26a9055_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_bdf9ebc8-b523-4b4c-9b2b-be64c7851314_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_8b6d2c09-0dee-4ace-a2d1-8ea130d89be4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0f873ac4-7c17-49de-afbf-5d0ff603783b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2f1b33c5-82db-4094-b492-2eda5a153351_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fdd8d006-c24f-449f-a370-63a6c644c960_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d151015d-0693-4a38-8d8b-13ad3a760749_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ab0f542b-bfe2-4b98-9676-73d6c0a7eb13_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9c4113f5-bef9-4dc6-9819-9f64e1024736_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_da7ce09f-72b1-4ef9-9e95-d6e8618dde39_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>auph-20210805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c706e47-e7c4-45a6-976f-e0c2c621eb5e,g:cf0e529d-5d42-4d30-9e7d-fc368e360cf2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CoverPage" xlink:type="simple" xlink:href="auph-20210805.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1b0c6303-4b8a-4f87-8250-cd59ba0b86c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_DocumentType_1b0c6303-4b8a-4f87-8250-cd59ba0b86c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1458ca3f-c967-4c6b-bb0e-8c1291e46865" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_DocumentPeriodEndDate_1458ca3f-c967-4c6b-bb0e-8c1291e46865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3adfdb38-5845-40e7-b797-0cd3127a0a16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityRegistrantName_3adfdb38-5845-40e7-b797-0cd3127a0a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f4707977-18bb-49eb-b5c5-0d453c2660f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f4707977-18bb-49eb-b5c5-0d453c2660f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_31925d7c-d386-44b6-aed0-1994a490c208" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityFileNumber_31925d7c-d386-44b6-aed0-1994a490c208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_96296f11-6f4d-4a8d-a0f4-e05375ee751d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityTaxIdentificationNumber_96296f11-6f4d-4a8d-a0f4-e05375ee751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7e31e780-ddeb-435b-a57a-164de42b7bf7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityAddressAddressLine1_7e31e780-ddeb-435b-a57a-164de42b7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_57e051a7-ea2a-4b7a-a185-e20ea1c18b68" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityAddressCityOrTown_57e051a7-ea2a-4b7a-a185-e20ea1c18b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_185e0d97-9de7-4cd3-a677-39e32a1dc9df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityAddressStateOrProvince_185e0d97-9de7-4cd3-a677-39e32a1dc9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_520c6368-dbca-475c-9e9b-13f869b66906" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityAddressPostalZipCode_520c6368-dbca-475c-9e9b-13f869b66906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d7f8f4c7-b169-40a4-ba62-94ad3d88c9b9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_CityAreaCode_d7f8f4c7-b169-40a4-ba62-94ad3d88c9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2282730b-eef9-4650-b90a-573616ea414d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_LocalPhoneNumber_2282730b-eef9-4650-b90a-573616ea414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cbf8143e-0b79-497a-b026-98d9a4983f33" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_WrittenCommunications_cbf8143e-0b79-497a-b026-98d9a4983f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_dfa72c41-742e-4b0a-873c-1758113ba66e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_SolicitingMaterial_dfa72c41-742e-4b0a-873c-1758113ba66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f76d0e05-7942-4194-b437-fd168e583b1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_PreCommencementTenderOffer_f76d0e05-7942-4194-b437-fd168e583b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6e56a3fb-2552-4214-8a1e-2718fda1bcbb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6e56a3fb-2552-4214-8a1e-2718fda1bcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76c8d967-dcb4-4db3-a9a5-22dac1958928" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_Security12bTitle_76c8d967-dcb4-4db3-a9a5-22dac1958928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_671020f4-9672-42fd-830c-6ebcd5830c78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_TradingSymbol_671020f4-9672-42fd-830c-6ebcd5830c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cf1fe0da-db6c-4ab7-b987-fb12d01fd52c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_SecurityExchangeName_cf1fe0da-db6c-4ab7-b987-fb12d01fd52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_de712d5a-4e5c-4481-a01a-78d46d2013e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityEmergingGrowthCompany_de712d5a-4e5c-4481-a01a-78d46d2013e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8cfee63d-0ba6-44bd-ac0b-79192db6bc9d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_EntityCentralIndexKey_8cfee63d-0ba6-44bd-ac0b-79192db6bc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_700a8581-34c4-4bc5-a931-4ffd1db2ef20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5bcbfe1-2791-4f56-ba7c-edb23c2c109a" xlink:to="loc_dei_AmendmentFlag_700a8581-34c4-4bc5-a931-4ffd1db2ef20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>aurinalogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aurinalogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9A;&5R:64@
M4F5P;W-A    !9 #  (    4   0J) $  (    4   0O)*1  (    #-3@
M )*2  (    #-3@  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C$Z,#(Z,C @,3(Z-#8Z-3D ,C R,3HP
M,CHR," Q,CHT-CHU.0   %8 80!L &4 <@!I &4 ( !2 &4 < !O ', 80
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !G 38# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M65XX^*<_CW1[OP]\/K*XFAD@9[^_ECV+'"!E@,],C@D]N!UXU?V;/^1#O_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>auph-20210805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="auph-20210805.xsd" xlink:type="simple"/>
    <context id="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl80L2ZyYWc6NGRkZjU3MmEzZmUyNGQzYzg0ZGYxZjc4MjZjMDY5Y2UvdGFibGU6MjhmMWIwZjJjNTA4NDk2Mjk0ZTMwZjczMGJlYTgwMTIvdGFibGVyYW5nZToyOGYxYjBmMmM1MDg0OTYyOTRlMzBmNzMwYmVhODAxMl8xLTEtMS0xLTA_a8f5ff21-603a-404f-9255-726e21bf1b03">0001600620</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl80L2ZyYWc6NGRkZjU3MmEzZmUyNGQzYzg0ZGYxZjc4MjZjMDY5Y2UvdGFibGU6MjhmMWIwZjJjNTA4NDk2Mjk0ZTMwZjczMGJlYTgwMTIvdGFibGVyYW5nZToyOGYxYjBmMmM1MDg0OTYyOTRlMzBmNzMwYmVhODAxMl8yLTEtMS0xLTA_06cfe927-5741-4408-976c-10a4082f505c">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM3_d8cded71-7d91-4acf-b2b1-a85a7a22bc12">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18yMjU_95a8e758-32db-4580-8cbc-97cb3d82d075">2021-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM0_0f8f0007-7c45-4576-9750-9fbeeaddc168">Aurinia Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NzU0ZTYwZWIxMjg0NDE1OThmNjEzYWZmZDc5MzA2OTYvdGFibGVyYW5nZTo3NTRlNjBlYjEyODQ0MTU5OGY2MTNhZmZkNzkzMDY5Nl8wLTAtMS0xLTA_afd40e8b-901a-4700-bcfa-182aa2a02b98">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NzU0ZTYwZWIxMjg0NDE1OThmNjEzYWZmZDc5MzA2OTYvdGFibGVyYW5nZTo3NTRlNjBlYjEyODQ0MTU5OGY2MTNhZmZkNzkzMDY5Nl8wLTItMS0xLTA_bd7cadb9-70e9-42a2-bef6-7e701ce15c58">001-36421</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NzU0ZTYwZWIxMjg0NDE1OThmNjEzYWZmZDc5MzA2OTYvdGFibGVyYW5nZTo3NTRlNjBlYjEyODQ0MTU5OGY2MTNhZmZkNzkzMDY5Nl8wLTQtMS0xLTA_e65df63e-3949-4fb7-bb16-2f702eb403ef">46-4129078</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM1_b6543188-58e7-4e9d-b0eb-ca3ad3cd492a">#1203-4464 Markham Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMz_8cabe31d-76a1-48bd-847e-21a39bca0b1e">Victoria</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjM2_27c75ef5-9be3-4c15-a856-9a2df835722d">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjI5_ec22b039-d213-4293-a161-3169d65649bc">V8Z 7X8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMw_f784016b-9c9e-4578-bd1c-04ac3bfdb675">250</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMx_b6ca18cf-0f36-4e08-b7e0-4fb8bc5b8871">708-4272</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6MGQwOGE5NGEwNmUwNDdkNWE5ZTc1OTc1OWQ2NjM3N2UvdGFibGVyYW5nZTowZDA4YTk0YTA2ZTA0N2Q1YTllNzU5NzU5ZDY2Mzc3ZV8wLTAtMS0xLTA_6af21139-d741-4d5c-957c-b1c87e53681f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NjE2ZDAxMWE4MjllNDgzYzg4YWJmNjhiMTM2YjZhZDYvdGFibGVyYW5nZTo2MTZkMDExYTgyOWU0ODNjODhhYmY2OGIxMzZiNmFkNl8wLTAtMS0xLTA_caf37297-e97b-4f61-b421-6eaf089ba265">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6MThiYTVlMzIzNzI2NDdhMjhmNjg2NGMyMWI0YWJjOTUvdGFibGVyYW5nZToxOGJhNWUzMjM3MjY0N2EyOGY2ODY0YzIxYjRhYmM5NV8wLTAtMS0xLTA_80e45758-4777-4241-ab7e-5a9ac2c51d07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6OWYxNjE4YmJjZjZlNGNhMmFkMmI5NjdlM2UwYmQxZmQvdGFibGVyYW5nZTo5ZjE2MThiYmNmNmU0Y2EyYWQyYjk2N2UzZTBiZDFmZF8wLTAtMS0xLTA_2b2ae757-b892-453a-ac49-9df360dbc8d4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NTQ2YTdlNmM4ODIxNDA1MTkzNmIzZmQxZjFlOTViOGQvdGFibGVyYW5nZTo1NDZhN2U2Yzg4MjE0MDUxOTM2YjNmZDFmMWU5NWI4ZF8xLTAtMS0xLTA_e1b5ee2c-db37-428e-a9a9-1a9a77d57ea4">Common Shares, without par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NTQ2YTdlNmM4ODIxNDA1MTkzNmIzZmQxZjFlOTViOGQvdGFibGVyYW5nZTo1NDZhN2U2Yzg4MjE0MDUxOTM2YjNmZDFmMWU5NWI4ZF8xLTItMS0xLTA_f350af01-9bf1-48c4-8d4e-540c35f96eeb">AUPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7da6130d0988428fa1c538880e73cc68_D20210805-20210805"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGFibGU6NTQ2YTdlNmM4ODIxNDA1MTkzNmIzZmQxZjFlOTViOGQvdGFibGVyYW5nZTo1NDZhN2U2Yzg4MjE0MDUxOTM2YjNmZDFmMWU5NWI4ZF8xLTQtMS0xLTA_b5421e3b-b36b-40b6-aa75-7b907d145533">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="id56ce215ddeb49128c0bb2911ce01bab_D20210607-20210607"
      id="id3VybDovL2RvY3MudjEvZG9jOjkxMzM3MmVmZGI3OTQ1ZDZhNmI0YjQ5YmQ1NzBiMGQyL3NlYzo5MTMzNzJlZmRiNzk0NWQ2YTZiNGI0OWJkNTcwYjBkMl8xL2ZyYWc6MGRjZDliODhlYzY3NDZiOTk5MDIwY2FkZDJlNDEyM2MvdGV4dHJlZ2lvbjowZGNkOWI4OGVjNjc0NmI5OTkwMjBjYWRkMmU0MTIzY18xMjMy_058f5382-bc8f-43ed-9353-0a0111776b83">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140086674469224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th"><div>Jun. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aurinia Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4129078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">#1203-4464 Markham Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Victoria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V8Z 7X8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">708-4272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, without par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AUPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0001600620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MM;B-. .CL!_ ^[52YJUA#ZSE/RC&_P)02P,$%     @ ;X$%4Y^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*N??P2K8<<XY_M/P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( &^!!5,'04UB@0   +$    0
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MD@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !O@053EXJ[',     3 @
M"P              @ %N#P  7W)E;',O+G)E;'-02P$"% ,4    " !O@053
M&445]3<!   G @  #P              @ %7$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ ;X$%4R0>FZ*M    ^ $  !H              ( !NQ$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ;X$%4V60
M>9(9 0  SP,  !,              ( !H!(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  ZA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="auph-20210805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="auph-20210805.htm">auph-20210805.htm</File>
    <File>auph-20210805.xsd</File>
    <File>auph-20210805_lab.xml</File>
    <File>auph-20210805_pre.xml</File>
    <File>exhibit991_q22021pressrele.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "auph-20210805.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 2,
   "dts": {
    "inline": {
     "local": [
      "auph-20210805.htm"
     ]
    },
    "labelLink": {
     "local": [
      "auph-20210805_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "auph-20210805_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "auph-20210805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "auph",
   "nsuri": "http://www.auriniapharma.com/20210805",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20210805.htm",
      "contextRef": "i7da6130d0988428fa1c538880e73cc68_D20210805-20210805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.auriniapharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20210805.htm",
      "contextRef": "i7da6130d0988428fa1c538880e73cc68_D20210805-20210805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-21-015854-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-015854-xbrl.zip
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M3J43?NYW^]W /K)[%B!$*VRH=I\&%CZ= 'W3;OCUI@95NX!4,PT<VO#W5.R
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MP7\)Q)U;USV?>4L1.LWLLN7X+D?++9/XIS%(*TY$9_"CEX;!WO\#4$L#!!0
M   ( &^!!5,]FG%5=P(  )8'   1    875P:"TR,#(Q,#@P-2YX<V3-55M/
MVS 4?N^O\/(\Y]H+C6B1!D*:U%W$0/ VN<Y)8I'8F>W0\N^QW40E!0:5]C I
M4IQSON_<CW-ZMJTK] !2,<$77N2''@).1<9XL?!NKB_QB7>V'(U./V%\]^5J
MA2X$;6O@&IU+(!HRM&&Z1+<9J'N42U&C6R'OV0/!>.E(YZ)YE*PH-8K#.#K4
MRC2ALW *XQF&&1WC\81,\7PVS3&$-*;3.(+U!#X7*<U#F,3S#$^R<8S'61+B
M.<PRG--D>@+)-*1Y[(QN5:IH"35!)C&NTJU:>*7631H$F\W&WR2^D$40AV$4
MW'U;_7)0K\-6C-\/T-NUK'I\$ECUFBCHX:1MR@&<M))Q1IJ2R)KX5-2!S3D\
M"2<>(EI+MFXU7 I97T!.VDHOO);_:4G%<@:9J7L%MK(#P#.U)K( _9W4H!I"
MX:.>ER.$;%58W0BI$7^5WY4EFL_GP=;FZ:%=%5>"$NU&X\VR.#RV1QS%.(G\
MK<J\X$-NAX885YIP"L?X-E^XY_V+&/8]/BZ&GG=\#,Z8 NH7XB'(@-G.A3B,
MC(77@U!OD>P![]E#_X1SH9T5*^ED3<-X+G8"([))I'TF5Y#W*_1B+UX9%_=*
MB:125._,5M!(T8#4#-3SG7(&2@GYPK.;A?L)_EV1M6\BZ2$O' S;8=6!H4"U
MVF?2<_5C8[C*-*."76W^Y\0;"<<F;BC*W"&NT4?F;_G71H]8MO#.A?DG_"2%
MB<_*;ZZ^OG/?..][5F^Z-YY!;@AN_$)S]YH'X?V_!"/'1)9Z&AP2#DRU"K(?
M?.G.A^EVY [R%R(E%6VKXWG[L-ZD=<*^G-VZ!<-]VWT_VTDGV*W[<O0$4$L#
M!!0    ( &^!!5-.+1SR. H  *)=   5    875P:"TR,#(Q,#@P-5]L86(N
M>&ULU9Q=;]LX%H;O^RNXF9M=8%B3$D6)1=M!-],NBLVT19.B@UTL#'XF0FTI
MD)4F^?=+R79JV9)-2;:JN4D<ASI\SVL]AR)%Z^5O#_,9^*ZS19PFK\[P<W0&
M=")3%2?7K\Z^7+V#T=EOKY\]>_DW"/_\Y^<+\'LJ[^8ZR<%YIGFN%;B/\QOP
M5>G%-V"R= Z^IMFW^#N'\'5YT'EZ^YC%US<Y\)"'M_^;O?!EB*@F(=2A)) $
MG$(64@,UDIZD'M8BT+]>OY &Z<!C"@:*>) H'T&F0P6-]&FD?8JD\<J@LSCY
M]J+X(?A" YM<LBC_?'5VD^>W+R:3^_O[YP\BFSU/L^N)AY _6;<^6S5_V&E_
M[Y>M,6-L4O[WJ>DBKFMHP^+)GW]<7,H;/><P3A8Y3V31P2)^L2C?O$@ESTO/
M#^H"C2V*O^"Z&2S>@MB#/G[^L%!GKY\!L+0C2V?ZLS:@^/WE\_O&+MFD:#%)
M]'7QR7[269RJRYQG^047>F;5E]'RQUO]ZFP1SV]G>OW>3:9-?=A9EE6B%BI9
MH1+30N4O39U->L@_DMY\5^L1Q)7I?CB6QGV>?CB:W"M;'_3I!6]TTUOR\H1Z
MFZBASMVGKGI+/[WB8YT6:<YG YP6/[K9D#PKWKBPKU;=%('V%-.RGU7IWI"J
M'W*=*+VLEI70(%:OSNRKJ=+Q=#WJ7=F#IH0'0E-&K$QBAZS(CEM1)"E$4AJ"
M, V#*)CF3^?R5"?PR^6ZVS)V?>"S%IGD#41F>I'>9?+'6#:?U0U0=FPJ1K-H
MDO"Y7MSRU0%673'L+P6_?AKJ"W$O)S_DM_!J=C('9F-(/I45 ;-B4$^S[4Q3
MV9CI#S@65F29YD++Y]?I]XD]Q*;KH>(%+%Y A%=C^R\[X28[G\F;;*V-9_*
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M?O0V;)BZT=:K#J5BKQ.]2T1]](%+P]X4=TO"_N9=2\%G?1T7*Y])7FY^5#C
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M68.++70CAXC[.>2R3N^K]!NNQG,FE8U>%"0Z;8B,.I 0*! ;&7<,I+9:#0C
M(^.]2.#C)^'UBKXQ$N^KIFQN/L&B;)6HFC_\&N;"IR(%88FR4A%)P9!@G"$T
M)L&X\=0S/0 1+]GN!808+Q [ZSD*'DXQF\N;.G?"?T;]X:2^K)I\<U(GF!?2
M4'3?$&9#(-(!XJVB(C1)A=IH38LA%HP>KO2B18Z=EN'4'@4\'\H5_'&Y#I#G
M@CFN$@J1A-5$RJ")AT0))L722X?I.K6#D?+=;B\LU-BQ>*6.HV#@PE^?)M2J
M+,K;DN5N(DYSIPO&B"YD(M+;1#PM)%9N2A@%8!1+@P'Q R=ZT:''3L<0"H\"
ME>.4, 3;NS>L\H#-#0@&QE*2$BYW4JA O#*>,"T32!Y,*,Q@F+S@0"]$S-@1
MV579,>%Q@A\_YHOZJIHK@RPS;PAXC@570.\]LXH I^!9Q&U2#[>I/#/?"PW[
MDZ#Q2E7'!$:7+WW,Y[G^5E81:R^K@"9,KEV"MO9*@GB-V9-P(+AG*;I4#$W'
M$Q]Z(>)^$D1VT7=,G)S7V\:O_EMNNJ1:\;9IHRU)(2+M1D7BP 7"1&&U"UH[
M.ER%^Y('_5I@]">!Y/7BOC$B[0)XG,%W?B=3V$)&+,Z9=EBF>XE2:$XPQTXB
M61M=< - \=!F/PQ&W I]M8!O'/CV5LKJ?%E7]R46YY8;00,!*-!WK2@)CGJB
MC-!,@Y=,#E&9/+7;#X 1=T!W$O*-(?B2RZ:!ZJ1>KR^KNS)J.T<9+),"" T&
M)^ P$PJ4:^)L<EAL6U$(,0 )+QKOA\.(^Y^[2_K&3'RN5V4LF[):_(Z)3R[]
M:IX*;WB4C!C) 5-CA-D:$0DSRC(F<(G3,  0SRWWHV'$_<T=Q7QC%,XSM!P#
MIKW=W;[VIG'^6* ?\\+H1+%@(L:UCQ8PASN=%(84B6D+RHK AD#BQQ[T0V/$
M/<Z!Q!T7(J?;[27DAW/1H+0712!<*9P+9Y)8SP#58K9(GJ%X87A0GOG1#Y<1
M-ST'%?JMMQB(E[A-WC >+LIF!7.C(VZ$VI 4@R0R!:RIG5>$\^0C<\HZ/D1'
MZZG=?E",N,VYDY!O#,%%]NWS<I]OUJ%>S;5A&*]"$G2^I;=(Q H:B880DVH_
MFB$(>&2T7_A'W,I\O80C60#>7\>EKQ;0/200"U8 39ZDH".1/F 9[2SN>H'Q
M1%F1%(\#+@(/;?<C8<0=RYT%'46G\OT:\@*!_G>NKYHE;G<;7]W@[P;]59Y(
M4#@-:1GQE'EB;)(Z<<H$#'<O[$47^CVD-?I>Y>[RCH*2$Y0L^]4IIC[7_X&;
MN8T%@!8):VO?/1N0B(\T8/+,'$?T0W3#W5)_8KP?&2-N7^XNZ1LS<8S9<&HS
MX@\KOY@;2KW%.IH(V3X8'Z+"_$>T@F#MA%) \?UON@,+CXSV8V#$'<S72SA8
M[-_-GHEWA@>.]NY^:%_:Q_6/]OX'4$L#!!0    ( &^!!5,N @&7B"D  -W,
M 0 >    97AH:6)I=#DY,5]Q,C(P,C%P<F5S<W)E;&4N:'1M[7UK5]M(MNCW
M^ROJI#,]9%W9L>0WI+.6 W2'<PAD@,S<^71662K;ZL@JMQX0SZ^_>^\JR?)#
M8!-C9%"OU0'T*%7M]ZMV??BOD\OCFW]_/66C:.RQK]\^G9\=LS>5]^__53]^
M__[DYH1]OOERSAK5FLEN NZ';N1*GWOOWY]>O&%O1E$T.7S__N[NKGI7K\I@
M^/[FZCT.U7CO21F*JA,Y;SY^P"OPK^#.Q__SX;\J%78B[7@L_(C9@>"1<%@<
MNOZ0_<L1X7=6J>BGCN5D&KC#4<2LFF6R?\G@NWO+U?W(C3SQ,1GGPWOU]X?W
M])$/?>E,/WYPW%OF.K^]<9MUJ],U:P/>Y\T&[W:X7:^)3JUMBX;=;UC]_S5A
MDN_A<?5.&$T]\=N;L>M71@*_?VB:S:HUB8[N7"<:'9JUVM_>S#T:B1]1A7ON
MT#^D"</=@?0CF$@  ZM?T_$_?HAXWQ/)NWT9."*HV-+S^"04A\DO1XX;3CP^
M/71]S_5%A5XZ&O-@"//JRRB2X\,FS.E6!)%K<T]_GZ:B;L^F6ZVI*4<PG<A)
MOJQO5^G6^\A9OE>WJE:]GGN[5C5S[SW7L(VUAGU/D%#0 ("'$^[_]J;^)GEA
MPAT'"/*PQLQ)E!EO.X]:DQ_X\-$BU2RB4F%1TU(R"(PK@\-?:O3?$=ZI#/C8
M]::'?[]QQR)D%^*.7<DQ]_]NA,"PE5 $[D ]&+K_$4 .\&GZ\TX1=QO&(0I+
MB)UHY?3'R.V[$>MVJV9*PAG0)?/1+[6;M/KLPKNY,"(F<,=#QKWHMS<\#EP0
M*7(H>?7/R1#>"NQ55^>^9];JDQ^/X88ZK/]'RNZS%;TG_DJO+PJ##*YL$#@B
MN)?%'WIK>\AL/(1,LPG(['V[.KLXZ[&KTZ^75S?7[/KT^/+BA/WC6^_JYO2*
M]>#WZ[/_Q[Y<7MQ\OE;2]O>SB][%\5GO'%ZZ_G8.+^%35Z?'IQ<W[/+KZ57O
MYNSR FY_/OOC\SG\?W.]0M(]#")-&Q5/#&"V'5A.<B50"^C,<XJ"H[KB^@[\
M=5C!9[8.62N!+(UXZ$;P?7L.UHU%6%O(.+_^TK%,\RA9<!$F=30/9 NA];95
M;3'XM@?ZG+D^\T7$ G$K_%BP@0Q8- (-)6SI.^ROF < <T47!RVK\3=X 35W
M"(\&<LP&;A!&<X^]8QH,K$"([P4N]QZ$[)XCUZS6ZPB4AMED$QZY@F8(F$&L
MCD-V\/7Z]_ =H-H6[BU87HCK\V]?_^??%V?73[*L5K71?N3"I#(W#P/AP4IN
MQ5$D)X>5>K7169;T?:!&'.'-QYLO14+/FX_,054V7,51!Q)6P3AKU199"A]>
MQ58<WJ:7.K4:0U3.,#D5/*A$LN* 1<TJ3PR#^U=<(*;?ZL**S_XDVX_A'1<$
MN</$C\JWZG45?@H[1EYB(WC3P[?A;G^JB#+NC]TPQ+MR -1X*VU/AA,)5,N^
M]'HLDO38Z9<>OG$9A?%W/B.P/<3QR]3HQSP<D7RP\1?Q5PS.L@?0# VZZOJW
M(HS06PX1S6_K5KW:3BT 'K'_CGWQZR]FJW94KQDD;IYFQ;7'RM$B(2"EBGV6
M=2^4#Z0_$('P;0&<X'DHOOJ"C62((B^2#I\BM3=^_:79 4IGD^JXRDY/;NZ1
M:-K-1.N#YIE!VI]Q&+F#Z>Z==,+(/\^.;RZOSGH&^Q2 J01L?RR]>-QW>6I_
M]^(A3)$U%4<_$0\MSG8U_51@,J!38')?1SP8<UO$9,&%[,RWJ^S@HG=]TOL'
MX87UOGW]_(X=X"JLVI%^C_Z"-6GW1-\\EN,)]Z?ZYCN-8E!HJ !=D'8#U^>^
M#;8_V$IA[.&5U0Z. *YS5LC!*NN-94R2-/8]$88LG C;';CPM(1Q@CLW%"!E
M P&*=@(?"?'+/B/5ZV \+PBK1::N?'Z? 9_9VJH(D:/&_+M@DT .<;5PX8X'
MP%P8(48W(S%W(PSO4J 7-(X73^(0_,S)B&B5'9Q?O$.#PAW#.+?X"K=M-5KF
M151==!_9G#D :+21A1/;G.P9I?""F=/J27@N!DP&L&RTB\\O4D?(EN-Q[+O1
MU$A(*>2NP[X*Q/X?@1" 73XPV%=8E>LDGS\>N6+ 3I4)=2O8Y6#@VO "K$G#
MIIK0XF4<+!)50G..&$L_!!"!=2[AL;'$]<5CQD-V?/G/LY,*N3DP87@C"EP;
MEQ<245$LW5<T-8%128'C6K_!6N#R=03OA>S.C<  8"%0#M"FS6'ZJ5,!;_:!
M5%,7G\"Z[!Y6V;\$?1*6,% 0B$8@+6GH: 18F_,R)B+ USC*6AP1/AX%"/\^
M]^AB.!(B,O08:N0[X7F5B71#[7P. WF'\P[Q@83&"$)W,OB.Q  \A8,O$10@
M%J^'0GP'LKIC<@(V:X3X=9%(\9NVC#V8EN,H,H41?"$<@I]>O08;LH@$\N1Q
M)%TD$H&T1J'YL*J)9?\X^$M0G9$U&\0!"BO$-U"-D=!L;Q[R,X G]#%CRR10
M )<"J0$Z1X,&81E&LMT)$@@A@?M^#,)W,<*4#G8'-BBJ:*!1'!"$R%"0B=JH
MX4??-FNIF8KOH40V &%1A!(AD4[QA&Z"]R*":4*&\*BE*0O<9 E\\1]!W^@#
M.PW<:(X.- 1P4$DS"?AD2A0VDA,QB#T/_K)!%I"L"E $*195\W8#E%.1@"$"
MD @/T4PNC:P=47Y>T^-*H+W*/B?N9+C/*\VU.5>O_5I)^']DXZ*DZ\$4&8N
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MUZPVYU+;I-+='PBG:!3FUB,MT%\CLY-C_5$T0:85(O,$Z:A*@!T0(PA\48D
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M     &%U<&@M,C R,3 X,#4N:'1M4$L! A0#%     @ ;X$%4SV:<55W @
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M=#DY,5]Q,C(P,C%P<F5S<W)E;&4N:'1M4$L%!@     %  4 4 $   E4
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
